Nature Communications (Sep 2020)
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity
- Gabriele Manzella,
- Leonie D. Schreck,
- Willemijn B. Breunis,
- Jan Molenaar,
- Hans Merks,
- Frederic G. Barr,
- Wenyue Sun,
- Michaela Römmele,
- Luduo Zhang,
- Joelle Tchinda,
- Quy A. Ngo,
- Peter Bode,
- Olivier Delattre,
- Didier Surdez,
- Bharat Rekhi,
- Felix K. Niggli,
- Beat W. Schäfer,
- Marco Wachtel
Affiliations
- Gabriele Manzella
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Leonie D. Schreck
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Willemijn B. Breunis
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Jan Molenaar
- Princess Máxima Center for Pediatric Oncology
- Hans Merks
- Princess Máxima Center for Pediatric Oncology
- Frederic G. Barr
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute
- Wenyue Sun
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute
- Michaela Römmele
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Luduo Zhang
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Joelle Tchinda
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Quy A. Ngo
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Peter Bode
- University Hospital Zurich, Institute of Surgical Pathology
- Olivier Delattre
- France INSERM U830, Équipe Labellisé LNCC, PSL Université, SIREDO Oncology Centre, Institut Curie
- Didier Surdez
- France INSERM U830, Équipe Labellisé LNCC, PSL Université, SIREDO Oncology Centre, Institut Curie
- Bharat Rekhi
- Tata Memorial Hospital, Department of Pathology
- Felix K. Niggli
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Beat W. Schäfer
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- Marco Wachtel
- University Children’s Hospital, Department of Oncology and Children’s Research Center
- DOI
- https://doi.org/10.1038/s41467-020-18388-7
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Patient-specific precision medicine approaches are important for future cancer therapies. Here, the authors show that functional drug profiling with Rhabdomyosarcoma cells isolated from PDX and primary patient tumors uncovers patient-specific vulnerabilities.
